January 16, 2024
HIROTSU Bio Science Inc.

Information page for medical professionals is now available.
－Provides professional information about “N-NOSE”.－HIROTSU Bio Science Inc. (Head Office: Chiyoda-ku, Tokyo; Representative; Takaaki
Hirotsu (Hereinafter referred to as “HIROTSU”)), has launched an "Information for
Medical Professionals" page with specialized information on the N-NOSE technology inorder to promote a better understanding of the N-NOSE nematode cancer test.
Thanks to your support, more than 500,000 people have used the "N-NOSE" nematode cancer
test since its launch in 2020, and more than 2,000 companies have introduced the test. Alongwith the expansion of the service, we have received requests from many people, including
medical professionals, for a more detailed understanding of the "N-NOSE" technology. In
response, we have decided to open an information page exclusively for medical professionals
as a place to provide further information.
https://hbio.jp/medical/

This page for medical professionals provides information to understand the performance of thetest, such as sensitivity, specificity, and positive predictive value, as well as abstracts of basicand clinical research on N-NOSE, summaries of major research papers, and information on thepractical application of N-NOSE.
We will continue to focus on research and development to make the world a better place forearly detection of cancer, and will continuously provide information to our customers, medical
professionals, and all other stakeholders.
■ About HIROTSU Bio Science
We as HIROTSU aim to protect the health and future security of people through research,development, and practical application of unique technology that utilize the capabilities ofliving organisms. Established in 2016, N-NOSE was put into practical use thanks to ourresearchers` abundance of ideas and tireless efforts. Despite the importance of extendinghealthy life expectancy being emphasized, it is said that one in every two people will bediagnosed with cancer in this age of 100-year life expectancy. We strive to contribute tosolving these social issues with our groundbreaking “bio-diagnoses” technology that utilizes
the power of nematodes.
Company Name

: HIROTSU Bio Science Inc.

Headquarters: 22F New Otani Garden Court, 4-1 Kioi-cho, Chiyoda-ku, Tokyo

Representative: Takaaki Hirotsu, CEODate of Establishment : August 2016
Main Service: Research, development, and marketing of cancer screenings usingnematodes and nematode olfactory sensors

Official Website: https://hbio.jp/en/■ About “N-NOSE”
A primary screening test for cancer that utilizes the highly accurate detection of cancer-specificodors in human urine by the nematode C. elegans, which has a very good sense of smell. By
simply submitting urine, the test is simple, inexpensive, highly accurate, and provides a wholebody comprehensive examination of early-stage cancer risk.
Official Service Website: https://lp.n-nose.com/■ About “N-NOSE plus Pancreas”
N-NOSE's next-generation "Cancer Type Specific Test". This test uses a "special nematode"
genetically engineered from the nematode C. elegans that specifically reacts only to the smellof pancreatic cancer. This "special nematode" has a high ability to distinguish between
pancreatic cancer and other cancers, enabling non-invasive detection of early-stage pancreaticcancer.
Official Service Website: https://lp.n-nose.com/suizou/■ About “N-NOSE Animals”“N-NOSE Dogs” and “N-NOSE Cats” developed based on the N-NOSE technology. Up until
now, there has not been an easily accessible cancer screening test for pets. Just like N-NOSE
for humans, starting in 2023, an easy cancer risk screening only requiring urine for both catsand dogs has been made available due to this product.
Official Service Website: https://lp.n-nose.com/animal/

Press Contact
HIROTSU Bio Science PR
E-mail：press@hbio.jp